A three-judge panel on the U.S. Court of Appeals for the Fifth Circuit blocked the FDA's 2023 rule that let mifepristone, the chemical abortion drug, be prescribed remotely and shipped through the mail, ruling that Louisiana proved the policy causes irreparable harm to the state and its laws protecting unborn life.

The unanimous decision reinstates the requirement that women see a medical professional in person before obtaining mifepristone. It sets the stage for what could become the next major abortion fight at the Supreme Court, where drug companies have already filed emergency motions to undo the ruling.

The ruling is the most significant federal court action on mifepristone since the Biden administration made its pandemic-era loosening of the drug's safety restrictions permanent in 2023. For states like Louisiana that restrict abortion, the decision offers the first real judicial check on a regulatory scheme that, by the court's own finding, facilitated nearly 1,000 illegal abortions per month inside the state's borders.

What the Fifth Circuit found, and why it matters

Circuit Judge Kyle Duncan, writing for the panel, laid out a blistering assessment of the FDA's regulatory conduct. The opinion, joined by Judges Leslie Southwick and Kurt Engelhardt, found that Louisiana has standing to sue, faces irreparable harm, and is likely to succeed on the merits of its challenge under the Administrative Procedure Act.

Judge Duncan, as reported by Breitbart News, wrote:

"As discussed, the 2023 REMS injures Louisiana by undermining its laws protecting unborn human life and also by causing it to spend Medicaid funds on emergency care for women harmed by mifepristone. Both injuries are irreparable."

The court did not stop there. Duncan addressed the mechanism of harm directly, noting that the FDA's decision to end the in-person dispensing requirement opened the door for out-of-state providers to prescribe mifepristone remotely to Louisiana women, precisely the outcome pro-life states had warned about.

Duncan wrote that "ensuring out-of-state medical providers could prescribe mifepristone to women in states that restrict abortion was a goal of the regulation." That sentence alone captures the core of the dispute: the Biden-era FDA did not merely relax a safety protocol. It engineered a workaround for state abortion laws.

The broader pattern of Biden-era federal agencies acting against pro-life interests has drawn sustained scrutiny, and this ruling adds a new chapter.

The FDA's data problem

One of the most damaging sections of the opinion targets the FDA's own evidentiary record. Judge Duncan noted that the agency had previously eliminated the requirement to report mifepristone's adverse events to its FDA Adverse Event Reporting System, known as FAERS. Then, when it came time to justify loosening safety guardrails, the FDA pointed to the absence of reported problems.

Duncan called this reasoning incoherent:

"Obviously, it's unreasonable for an agency to eliminate a reporting requirement for a thing and then use the resulting absence of data to support its decision."

He also noted that the FDA relied on literature about remote prescription of mifepristone, despite the agency's own admission that the literature "did not affirmatively support its position." In other words, the FDA loosened safety restrictions on a drug while conceding it lacked the data to prove the changes were safe.

The panel pointed out that this was the third time the Fifth Circuit had found the agency's "progressive relaxation of mifepristone's guardrails likely lacked a basis in data and scientific literature." The FDA itself, the court noted, now concedes the regulations were marred by "procedural deficits" and a "lack of adequate consideration."

That concession is remarkable. An earlier federal judge had allowed mail-order abortion pills to continue but warned the FDA its patience had limits. The Fifth Circuit apparently ran out of patience first.

A timeline of loosening restrictions

The FDA first approved mifepristone in 2000, classifying pregnancy as an "illness." At that time, the Risk Evaluation and Mitigation Strategy required only doctors to prescribe the drug after three in-person visits and directed them to report serious adverse events.

In 2016, the agency scaled back reporting, requiring health care workers to report only fatalities. The Biden administration temporarily suspended the in-person dispensing requirement in 2021, then made that suspension permanent in 2023.

Each step widened access and weakened oversight. Louisiana and Rosalie Markezich, a woman who alleges her boyfriend ordered abortion drugs online from California and coerced her into taking them, filed suit against the FDA in October 2025. In April, a district court declined to block the mail-order regulation but wrote that Louisiana was "likely to succeed" in its challenge. The Fifth Circuit disagreed with the lower court's decision to let the rule stand during litigation and moved to block it.

The scale of mail-order abortions

The numbers tell a stark story. The Guttmacher Institute estimated in 2023 that medication abortions accounted for 63 percent of all abortions within the formal U.S. healthcare system, up from 53 percent in 2020 and 39 percent in 2017. By 2025, the organization estimated that 91,000 telehealth abortions were provided under blue-state shield laws to people in states with abortion restrictions.

National Review reported that telehealth abortions grew sharply, with roughly 247,000 conducted in 2024 and approximately 28 percent of all U.S. abortions done via telehealth by June 2025. The Fifth Circuit's ruling, if it holds, would shut down that pipeline.

Louisiana's attorney general celebrates

Louisiana Attorney General Liz Murrill did not mince words after the ruling. She credited her office and the Alliance Defending Freedom for the outcome.

"The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over, thanks to the hard work of my office and our friends at ADFLegal. I look forward to continuing to defend women and babies as this case continues."

Students for Life President Kristan Hawkins, as Fox News reported, said: "This is a win we've been waiting for, and we pray it holds."

The pro-life legal movement has notched several courtroom victories in recent years, including a seven-figure settlement for pro-life activist Mark Houck after a failed federal prosecution.

Drug companies rush to the Supreme Court

Danco Laboratories and GenBioPro, which intervened as defendants in the case, wasted no time. After the Fifth Circuit's ruling, both companies filed emergency motions with the Supreme Court asking it to block the appeals court decision. The Washington Times reported that Danco said the ruling was causing "immediate chaos" and "irreparable harm."

Judge Duncan addressed the financial argument head-on. He acknowledged that a stay would impose costs on Danco but wrote that the company "exaggerates by predicting a stay would destroy any 'valid legal framework for distributing' the drug." A stay, he noted, "would only pause a method of prescribing mifepristone that began five years ago and was formally approved only three years ago."

The mifepristone makers' emergency appeal to the Supreme Court now puts the justices squarely in the middle of the fight once again.

The ruling carries nationwide practical effect. The Fifth Circuit acknowledged as much, noting that a stay under Section 705 of the APA "would, as a practical matter, have a nationwide effect." AP News reported that the decision would end mail-order distribution of mifepristone and limit its use to the seventh week of pregnancy, requiring it to be administered in the presence of a physician.

The public interest question

Perhaps the most pointed passage in the opinion addressed the public interest, the standard courts weigh when deciding whether to block a regulation during litigation. Judge Duncan wrote:

"Neither the FDA nor the public has any interest in enforcing a regulation that violates federal law. We have now three times found that the agency's progressive relaxation of mifepristone's guardrails likely lacked a basis in data and scientific literature. FDA itself now concedes the regulations were marred by 'procedural deficits' and a 'lack of adequate consideration.' The public interest is not served by perpetuating a medical practice whose safety the agency admits was inadequately studied. Indeed, the public interest demands the opposite."

That framing flips the usual progressive argument on its head. Abortion advocates have long cast any restriction on mifepristone as an attack on women's health care. The Fifth Circuit says the real threat to women's health came from an agency that loosened safety rules without adequate evidence, then hid behind the data gap it created.

Other federal courts have also pushed back on state-level attempts to force pro-life organizations into complicity with abortion, as seen when a federal judge struck down an Oregon law forcing a pro-life group to fund abortion coverage.

What comes next

The Supreme Court has intervened before to keep mifepristone available during earlier rounds of litigation. Whether the justices do so again will determine whether the Fifth Circuit's ruling takes practical effect or sits on hold while the case grinds forward.

The FDA under the Trump administration has asked courts to let the mail-order policy continue while the agency conducts a safety review of mifepristone, a position that put the current administration at odds with the Fifth Circuit panel.

Open questions remain. What will the Supreme Court do with the emergency motions? Will the FDA's safety review produce findings that change the legal calculus? And will other states follow Louisiana's lead?

For now, the Fifth Circuit has said what should have been obvious from the start: an agency that scrubs its own safety data, ignores its own scientific gaps, and then uses the silence as proof of safety has no business demanding public trust, or judicial deference.